Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

18.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Bipyridine and Phenanthroline Incorporation into the Macropa Scaffold on Ba(II)/Ra(II) Chelation.

Inorganic chemistry·2026
Same author

Harnessing Immunogenic PANoptosis With Iridium(III) Biradical Photosensitizers for Melanoma Photoimmunotherapy.

Angewandte Chemie (International ed. in English)·2026
Same author

Occurrence, Sources, and Export Rates of Ti-Bearing and Ce-Bearing (Nano)particles in the Seine River Where Engineered Nanoparticles Reach Natural Background Levels.

Environmental science & technology·2026
Same author

A coordinated transcriptional program controls de novo Golgi biogenesis.

The EMBO journal·2026
Same author

Organometallic Complexes with an Indolo[2,3-<i>c</i>]Quinoline-Derived Ligand: From Structural Features and Solution Speciation to Nanoformulation for Enhanced Therapeutic Potential.

Inorganic chemistry·2026
Same author

Mechanistic Insights Into the Oxidative Reactivity of 2-Selenouridine in tRNA.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026

Related Experiment Video

Updated: Dec 28, 2025

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
07:12

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

8.1K

A Maltol-Containing Ruthenium Polypyridyl Complex as a Potential Anticancer Agent.

Anna Notaro1, Marta Jakubaszek1,2, Severin Koch3

  • 1Chimie ParisTech, PSL University, CNRS, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, 75005, Paris, France.

Chemistry (Weinheim an Der Bergstrasse, Germany)
|February 18, 2020
PubMed
Summary

A novel ruthenium complex, [Ru(DIP)2(mal)](PF6), shows significant anticancer activity, outperforming cisplatin in preliminary tests. This metal-based drug effectively targets cancer cells and mitochondrial metabolism.

Keywords:
DNAbioinorganic chemistrycancermedicinal inorganic chemistryruthenium

More Related Videos

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes
10:51

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

Published on: April 10, 2015

12.6K
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.3K

Related Experiment Videos

Last Updated: Dec 28, 2025

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
07:12

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

8.1K
The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes
10:51

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

Published on: April 10, 2015

12.6K
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.3K

Area of Science:

  • Medicinal Chemistry
  • Inorganic Chemistry
  • Cancer Research

Background:

  • Cancer remains a leading global cause of death, with chemotherapy as a primary treatment despite severe side effects.
  • Metal-based drugs offer advantages over organic compounds, gaining traction with cisplatin's market approval.
  • Ruthenium complexes, like the previously reported [Ru(DIP)2(sq)](PF6), show promise as chemotherapeutic agents.

Purpose of the Study:

  • To synthesize and characterize a new ruthenium complex, [Ru(DIP)2(mal)](PF6), incorporating the FDA-approved ligand maltol (mal).
  • To evaluate the stability and biological activity of [Ru(DIP)2(mal)](PF6) as a potential anticancer agent.
  • To compare its efficacy against cisplatin and investigate its cellular uptake and mechanism of action.

Main Methods:

  • Synthesis and full characterization of the ruthenium complex [Ru(DIP)2(mal)](PF6).
  • Assessment of complex stability under physiological conditions.
  • In vitro cytotoxicity testing on various cell lines and 2D models.
  • Evaluation using HeLa Multicellular Tumor Spheroids (MCTS).
  • Cellular uptake studies and mitochondrial metabolism assays.

Main Results:

  • The ruthenium complex [Ru(DIP)2(mal)](PF6) was successfully synthesized and characterized.
  • The compound demonstrated good stability in solution, mimicking physiological conditions.
  • Cytotoxicity tests revealed higher activity compared to cisplatin against tested cancer cell lines and MCTS.
  • [Ru(DIP)2(mal)](PF6) was efficiently internalized by HeLa cells via passive transport.
  • The complex significantly impacted mitochondrial metabolism in cancer cells.

Conclusions:

  • [Ru(DIP)2(mal)](PF6) is a promising metal-based anticancer agent with superior efficacy to cisplatin in initial evaluations.
  • The compound's ability to be internalized and disrupt mitochondrial function highlights its therapeutic potential.
  • The use of an FDA-approved ligand (maltol) is advantageous for potential clinical translation.